on your mRNA therapeutic and vaccine development
The economics of synthetic mRNA capping strategies
An essential part of any mRNA compound is the 5’ cap structure, which is critical to the stability, expression, and immunogenicity of an mRNA. In vitro–transcribed mRNA is not capped by default, so capping must be built into the manufacturing process using one of the three available methods: Enzymatic capping, ARCA (Anti-Reverse Cap Analog) and CleanCap® capping technology.
The inherent nature and manufacturing requirements of the three technologies available for capping synthesized mRNAs can have a varied impact to the overall economics of the mRNA manufacturing requirements. TriLink BioTechnologies commissioned a third-party study, conducted by Health Advances LLC, to analyze the manufacturing costs of the three methods of mRNA capping.
This analysis included conversations with 30 subject matter experts, outside of TriLink, who are developing mRNA therapeutics.
4+
Days saved
GMP production batches using CleanCap technology saved on average 4+ days compared to enzymatic and ARCA methods.
50%
Less PD time
CleanCap capping solution reduces process development time by an estimated 50% compared to ARCA and enzymatic capping.
>20%
Lower overall cost
mRNA manufacturing utilizing CleanCap technology saw an estimated 20-40% lower total costs than other methods.
Using the insights and data, we have built a customer verified assessment tool to help you calculate the savings you may see by using the CleanCap capping solution in your mRNA manufacturing. Request a consult with our experts to calculate your potential savings in using CleanCap in you process over enzymatic capping strategy.
Read the Application Note
This technical note includes analysis and qualitative quotations from customer experiences about the relative cost of each available capping methods.
© 2024 TriLink BioTechnologies. All rights reserved. Terms | Privacy notice